BRENNEN

Industries / Health / Healthcare / Pharmacy / Specialty pharmacy

Patient support

Patient support is the help that keeps a patient on an expensive drug: drug makers' hub programs (company-paid services that check a patient's insurance, find money for the copay and arrange the first fill), copay cards, charity funds, nurse and pharmacist check-ins, and the rules that govern them.

7

Milestones achieved, from 2014 to 2023.

2

To watch for: announced, not yet confirmed outside.

2

Open deliverables. Nobody has shipped them.

The road

AchievedWatch forOpen

Achieved

  1. 2014

    Rules for coupons and charities

    A copay coupon or card is money a drug maker gives an insured patient toward the share of a drug's price the plan leaves to them. In September 2014 the US Department of Health and Human Services' Office of Inspector General (OIG) warned that coupons used for drugs paid by Medicare or other federal programs can break the federal anti-kickback law, after its own study found that makers' safeguards might not stop such use. Makers who want to help those patients may give to independent charities instead, under conditions OIG first set out in November 2005; in May 2014 it warned charities against disease funds drawn so narrowly that a donor's money mainly paid for the donor's own drug.

    oig.hhs.govoig.hhs.gov

    Credit

    HHS Office of Inspector General

  2. 2017

    Coupons raise drug spending

    Leemore Dafny, Christopher Ody and Matthew Schmitt compared US states and patients where copay coupons were and were not allowed, for brand-name drugs that first met generic competition between 2007 and 2010. Coupons raised branded sales by more than 60%, all of it at the expense of the bioequivalent generics, and added an estimated $30 million to $120 million in spending per drug over five years, $700 million to $2.7 billion across the drugs studied.

    LessonHelp that lowers the patient's bill can raise the plan's.

    nber.org

    Credit

    Leemore Dafny, Christopher Ody and Matthew Schmitt, American Economic Journal: Economic Policy

  3. 2017

    Charity gifts become kickbacks

    On 20 December 2017 United Therapeutics, which makes drugs for pulmonary arterial hypertension, agreed to pay $210 million to settle US claims that it used the charity Caring Voice Coalition as a channel to pay Medicare patients' copays for its own drugs. On 28 November 2017 OIG had withdrawn the favorable advisory opinion, a formal ruling that an arrangement would not draw sanctions, that it gave the charity in 2006. By April 2019 seven companies had paid more than $700 million to settle such investigations, by the count of lawyers at Skadden. The cases continue: in September 2026 Dompé U.S. agreed to pay $32 million over Medicare copays for its eye drug Oxervate paid through two foundations, after disclosing the conduct itself.

    LessonA charity that is independent on paper is not independent if the donor steers which patients and which drug its money covers.

    agg.comskadden.comjustice.gov

    Credit

    US Department of Justice and the US Attorney's Office for Massachusetts, with HHS-OIG

  4. 2019

    Charities cover costly drugs

    Johns Hopkins researchers studied the six largest independent charity foundations and their 274 disease funds in 2018. 97% of the funds required patients to have insurance, which shut out the uninsured, and the drugs they covered had a median yearly cost of $1,157 per patient against $367 for drugs they did not cover. Off-patent brand-name drugs costing more than $10,000 a year were covered by 3.1 funds on average, their generic copies by 1.2.

    europepmc.org

    Credit

    So-Yeon Kang, Aditi Sen, Ge Bai and Gerard Anderson, Johns Hopkins University

  5. 2020

    Adherence measured, unevenly

    Adherence is often measured as the proportion of days covered (PDC): the share of days in a period for which fill records show the patient had the drug on hand. At Emory Healthcare in Atlanta, 204 patients whose oral cancer drugs were filled by the health system's own specialty pharmacy had a mean PDC of 0.95, against 0.70 for patients filled by outside specialty pharmacies. A year earlier, pharmacists from Johns Hopkins, Vanderbilt, UC Davis and the University of Illinois had warned that specialty pharmacies calculate PDC in different ways, so their reported rates cannot be compared until each states its method.

    LessonA pharmacy's adherence figure says as much about how it counts days as about its patients.

    europepmc.orgeuropepmc.org

    Credit

    Colleen McCabe, Ryan Haumschild and colleagues, Emory Healthcare; Scott Canfield, Autumn Zuckerman and colleagues

  6. 2023

    Canada counts support programs

    In Canada, drug makers run patient support programs that help with insurance claims, funding and nursing care. A team led from the University of Toronto checked every prescription drug marketed in Canada on 23 August 2022: 256 of 2,556 drugs (10.0%), from 55 of 89 companies, had such a program, most often brand-name, biologic, rare-disease and high-priced drugs. Of the 256 programs, 90.2% helped with reimbursement and 87.1% offered clinical case management, often through outside administrators. The authors called for public transparency and independent evaluation.

    europepmc.org

    Credit

    Quinn Grundy, Joel Lexchin, Marc-André Gagnon, Mina Tadrous and colleagues, University of Toronto, York University and Carleton University

  7. 2023

    Court strikes accumulator rule

    A copay accumulator is a health plan rule under which a drug maker's copay help does not count toward the patient's deductible or yearly out-of-pocket limit, so the patient's own bills start again when the help runs out. A federal rule published in May 2020 let US insurers and plans decline to count such help; on 29 September 2023 Judge John D. Bates of the US District Court for the District of Columbia vacated it, because the agencies had read the same statutory and regulatory language in contradictory ways (HIV and Hepatitis Policy Institute v. HHS). In October 2024 HHS said it intended to propose a new rule; none was found in the Federal Register by 20 November 2026. States have acted instead: New Jersey became the 26th state with an anti-accumulator law in January 2026, by Drug Channels' count.

    govinfo.govgovinfo.govdrugchannels.net

    Credit

    the HIV and Hepatitis Policy Institute and its co-plaintiffs; Judge John D. Bates

Watch for

  1. Accumulator bans and premiums

    Pharmacy benefit managers argue that copay help raises premiums. Using insurers' medical loss ratio filings for 2014 to 2024, researchers report that small- and large-group premiums grew 20.8% from 2020 to 2024 in states that banned accumulators and 24.2% in states that did not, and found no statistically significant effect of the bans (an estimated $41.08 a year, with a 95% confidence interval of −$151.28 to $233.43).

    Achieved whenA group with no tie to drug makers, insurers or PBMs repeats the analysis and reaches the same result.

    europepmc.org

    Claimed by

    Yevgeniy Feyman and colleagues, National Pharmaceutical Council, with co-authors from IQVIA, the University of Maryland and the University of Chicago, November 2026

  2. Plans told what maximizers earn

    A copay maximizer spreads a drug maker's yearly copay help evenly over the year so that the plan collects all of it; its vendors can reportedly earn 25% or more of the help's value, by Drug Channels' account. The US Labor Department's final rule of 2 November 2026 on what pharmacy benefit managers must disclose to large self-insured employer plans says the services to be disclosed include copay accumulators, maximizers and "alternative funding programs", and that payment for them belongs in its catch-all "other" compensation. It applies to plan years beginning on or after 1 July 2027.

    Achieved whenPlans have received the first disclosures and an outside party publishes what accumulator and maximizer programs earned.

    govinfo.gov

    Claimed by

    US Department of Labor, November 2026

Open

  1. 01

    Copay program terms, one table

    A dated public table of the copay program terms for the 50 US specialty drugs with the highest spending: maximum yearly benefit, cap per fill, who is excluded (for example people on government insurance), and whether the maker cuts the benefit when it detects an accumulator or maximizer, each field linked to the public page it came from. Refresh it each quarter and keep every old version so changes can be seen.

    The brief
    Credit · unclaimed
  2. 02

    A copay math answer key

    300 made-up cases of a plan and a patient (deductible, out-of-pocket limit, coinsurance, monthly drug price, copay card limits), each under a standard plan, an accumulator and a maximizer, with the amounts the patient, the card and the plan pay in each month of the year, worked out by two people separately. Then score AI chat assistants on the same cases. All money and patients are made up.

    The brief
    Credit · unclaimed

Open 01 · the brief

Copay program terms, one table

Credit · unclaimed

The first to publish is credited on this line, and the deliverable moves from Open to Achieved.

What to build

A dated public table of the copay program terms for the 50 US specialty drugs with the highest spending: maximum yearly benefit, cap per fill, who is excluded (for example people on government insurance), and whether the maker cuts the benefit when it detects an accumulator or maximizer, each field linked to the public page it came from. Refresh it each quarter and keep every old version so changes can be seen.

Why it is still open

A 2024 primer by pharmacists and researchers at the University of Chicago and Vanderbilt gives one example, Janssen's anti-inflammatory programs, whose yearly funds drop from $20,000 to $6,000 if an accumulator or maximizer is identified, citing two program documents, and notes that published data are limited. Drug Channels' 2026 review counts plans that use accumulators and maximizers, not the terms makers set. No compiled table of terms was found.

pmc.ncbi.nlm.nih.gov

Built with what exists

A web agent such as Browser Use to collect public program pages and terms PDFs without signing up for anything (see the Note "Deleting 80% to start over"); an AI model to copy terms into a fixed form; CMS's public drug spending data to pick the drugs; Git for dated versions.

  1. First step

    Read the public terms for ten drugs this month and fill the form by hand to settle the fields.

  2. Done looks like

    50 drugs, every field sourced; a second person checks every field for 10 drugs and one in five fields for the rest, and the error rate is reported; after two refreshes, a list of which terms changed.

Open 02 · the brief

A copay math answer key

Credit · unclaimed

The first to publish is credited on this line, and the deliverable moves from Open to Achieved.

What to build

300 made-up cases of a plan and a patient (deductible, out-of-pocket limit, coinsurance, monthly drug price, copay card limits), each under a standard plan, an accumulator and a maximizer, with the amounts the patient, the card and the plan pay in each month of the year, worked out by two people separately. Then score AI chat assistants on the same cases. All money and patients are made up.

Why it is still open

Patient guides work through one or two cases by hand. Triage Cancer's 2026 guide, made with Pfizer, follows one made-up patient through four tables, and the 2024 primer uses one case. No public answer key, and no score for AI assistants on this arithmetic, was found.

triagecancer.org

Built with what exists

A reference calculator in Python or a spreadsheet; two human reviewers; three current AI models given the same prompts.

  1. First step

    Write the reference calculator for the three plan types and check it against 20 cases worked by hand.

  2. Done looks like

    300 cases where the two workers agree on every month, with disagreements logged and resolved; each AI model scored on exact match per month and on the year's total paid by the patient.